A prosztatarák gazdasági terhe nagy betegregiszterek alapján (The economic burden of prostate cancer. A systematic literature overview of registry-based studies)

INTRODUCTION: Prostate cancer, the most frequent malignant disease in males in Europe, accounts for a great proportion of health expenditures. AIM: A systematic review of registry-based studies about the cost-of-illness and related factors of prostate cancer, published in the last 10 years. METHOD: A MEDLINE-based literature review was carried out between January 1, 2003 and October 1, 2013. RESULTS: Fifteen peer-reviewed articles met the criteria of interest. In developed countries radiotherapy, surgical treatment and hormone therapy account for the greatest per capita costs. In Europe early stage tumours (4-7000 €, 2006), while in the USA metastatic prostate cancer (19 900-25 500 $, 2004) was associated with highest per capita expenses. In Europe the greatest costs incurred within the initial treatment (6400 €/6 months, 2008), while in the USA within the end-of-life care (depending on age: 62 200-93 400 $, 2010). CONCLUSIONS: Despite public health importance of prostate cancer, the cost-of-illness literature from Europe is relatively small.

Futures Studies in Finland

The development of futures studies and the future-oriented attitude of Finnish institutions and the government can serve as great example for other countries. This attitude appears in education and economy, issues in which Finland is highly competitive in. We introduce the futures studies-related organizations and the foresight system of Finland. An overview of the development of futures studies and the activities, purposes of foresight institutions, with a major emphasis on the Finland Futures Research Centre will be presented. The main question is how could other countries utilize the Finnish example? Societal changes depend on the environment and its historical background, making it quite a challenge to come up with an all-adaptable answer for this question. Thus we will only present guidelines and proposals regarding the development of strategy at the end of this paper.